Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

Key Points

• The study investigates how the R144C variant of CYP2C9 affects the metabolism of S-warfarin, a common anticoagulant.
• Analyzed the metabolic activity of S-warfarin in subjects with the R144C CYP2C9 variant.
• Evaluated enzyme kinetics to determine the extent of impairment.
• Included participants based on specific genotyping criteria.
• Found that individuals with the R144C variant exhibit significantly reduced S-warfarin metabolism, leading to increased plasma concentrations.
• Demonstrated a clear association between the R144C variant and altered anticoagulant effects, necessitating dose adjustments.